← Back to Search

CAR T-cell Therapy

Activated T Cells for Brain Cancer

Phase 1
Waitlist Available
Led By Jeremy Rudnick, MD
Research Sponsored by Jeremy Rudnick, M.D
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Recurrent glioblastoma
HLA-A1 and HLA-A2 positive
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at baseline visit and at time of recurrence. assessed up to 3 years.
Awards & highlights

Study Summary

This trial is testing if ATCs are safe and tolerable in people with cancer, and if they help with survival or quality of life.

Who is the study for?
This trial is for individuals with recurrent glioblastoma who are HLA-A1 and HLA-A2 positive and have had a complete resection of their tumor. It's not suitable for those with HIV/AIDS, hepatitis B or C, allergies to DMSO or gentamicin, significant heart or lung disease, or active infections needing treatment.Check my eligibility
What is being tested?
The study tests the safety and tolerability of autologous activated T cells (ATCs) in patients with recurrent glioblastoma. It aims to find the maximum tolerated dose while monitoring serious adverse events and treatment-related toxicities using NCI CTCAE V5 criteria.See study design
What are the potential side effects?
Potential side effects include Grade 3 or higher toxicities such as severe immune reactions, infusion-related complications, and possible worsening of underlying conditions due to ATC therapy as per NCI CTCAE Version 5 guidelines.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My brain cancer has come back after treatment.
Select...
I am HLA-A1 and HLA-A2 positive.
Select...
My tumor has been completely removed surgically.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at baseline visit and at time of recurrence. assessed up to 3 years.
This trial's timeline: 3 weeks for screening, Varies for treatment, and at baseline visit and at time of recurrence. assessed up to 3 years. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Grade 3 or higher toxicities, number of serious adverse events, and the number of treatment-related toxicities to find the maximum tolerated dose
Secondary outcome measures
Health-related quality of life parameters
Immune Response
Overall Response Rate (ORR)
+3 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Activated T cellsExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Jeremy Rudnick, M.DLead Sponsor
Kairos PharmaUNKNOWN
Jeremy Rudnick, MDPrincipal InvestigatorCedars-Sinai Medical Center
1 Previous Clinical Trials
36 Total Patients Enrolled
1 Trials studying Glioblastoma
36 Patients Enrolled for Glioblastoma

Media Library

Activated Autologous T Cells (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05341947 — Phase 1
Glioblastoma Research Study Groups: Activated T cells
Glioblastoma Clinical Trial 2023: Activated Autologous T Cells Highlights & Side Effects. Trial Name: NCT05341947 — Phase 1
Activated Autologous T Cells (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05341947 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could you elucidate the potential dangers of utilizing Activated T cells?

"Due to the sparse evidence for this treatment's safety and efficacy, Activated T cells have been assessed as a 1 on our team's scale of 1-3."

Answered by AI

Are there still opportunities to participate in this medical experiment?

"According to what is documented on clinicaltrials.gov, this study has stopped enrolling participants as of April 21st 2022. While it's no longer taking in patients, 1609 other medical trials are actively searching for candidates at the moment."

Answered by AI

Who else is applying?

What state do they live in?
New York
How old are they?
18 - 65
What site did they apply to?
Cedars-Sinai Medical Center
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma
Jeremy Rudnick, M.D 2022. "Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05341947.
All > Ependymoma > Brain Tumor
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top